164 related articles for article (PubMed ID: 27301678)
1. Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizers.
McIver ZA; Kryman MW; Choi Y; Coe BN; Schamerhorn GA; Linder MK; Davies KS; Hill JE; Sawada GA; Grayson JM; Detty MR
Bioorg Med Chem; 2016 Sep; 24(17):3918-3931. PubMed ID: 27301678
[TBL] [Abstract][Full Text] [Related]
2. Selenorhodamine photosensitizers for photodynamic therapy of P-glycoprotein-expressing cancer cells.
Hill JE; Linder MK; Davies KS; Sawada GA; Morgan J; Ohulchanskyy TY; Detty MR
J Med Chem; 2014 Oct; 57(20):8622-34. PubMed ID: 25250825
[TBL] [Abstract][Full Text] [Related]
3. Selenorhodamine photosensitizers with the Texas-red core for photodynamic therapy of cancer cells.
Kryman MW; Davies KS; Linder MK; Ohulchanskyy TY; Detty MR
Bioorg Med Chem; 2015 Aug; 23(15):4501-4507. PubMed ID: 26105712
[TBL] [Abstract][Full Text] [Related]
4. Extended rhodamine photosensitizers for photodynamic therapy of cancer cells.
Davies KS; Linder MK; Kryman MW; Detty MR
Bioorg Med Chem; 2016 Sep; 24(17):3908-3917. PubMed ID: 27246858
[TBL] [Abstract][Full Text] [Related]
5. Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo.
Holien T; Gederaas OA; Darvekar SR; Christensen E; Peng Q
Lasers Surg Med; 2018 Jul; 50(5):469-475. PubMed ID: 29460964
[TBL] [Abstract][Full Text] [Related]
6. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma.
Shiue LH; Couturier J; Lewis DE; Wei C; Ni X; Duvic M
Photodermatol Photoimmunol Photomed; 2015 Jul; 31(4):184-94. PubMed ID: 25772268
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal photochemotherapy induces bona fide immunogenic cell death.
Tatsuno K; Yamazaki T; Hanlon D; Han P; Robinson E; Sobolev O; Yurter A; Rivera-Molina F; Arshad N; Edelson RL; Galluzzi L
Cell Death Dis; 2019 Aug; 10(8):578. PubMed ID: 31371700
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
[TBL] [Abstract][Full Text] [Related]
9. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo.
Bladon J; Taylor P
J Clin Apher; 2002; 17(4):177-82. PubMed ID: 12494410
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies.
Russell-Jones R
Br J Dermatol; 2000 Jan; 142(1):16-21. PubMed ID: 10651689
[TBL] [Abstract][Full Text] [Related]
12. Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4+ T lymphocytes.
Zouboulis CC; Schmuth M; Doepfmer S; Dippel E; Orfanos CE
Dermatology; 1998; 196(3):305-8. PubMed ID: 9621137
[TBL] [Abstract][Full Text] [Related]
13. Extracorporeal photopheresis: what is it and when should it be used?
Scarisbrick J
Clin Exp Dermatol; 2009 Oct; 34(7):757-60. PubMed ID: 19663836
[TBL] [Abstract][Full Text] [Related]
14. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal photopheresis differentially regulates the expression of phosphorylated STAT-1 and STAT-5 in treated monocytes and T cells, respectively.
Bladon J; Taylor P
J Cutan Med Surg; 2004; 8(3):148-56. PubMed ID: 15578129
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal photopheresis: a focus on apoptosis and cytokines.
Bladon J; Taylor PC
J Dermatol Sci; 2006 Aug; 43(2):85-94. PubMed ID: 16797926
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T
Peacock A; Dehle F; Mesa Zapata OA; Prince HM; Gennari F; Taylor C
Value Health; 2022 Jun; 25(6):965-974. PubMed ID: 35667784
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group.
McKenna KE; Whittaker S; Rhodes LE; Taylor P; Lloyd J; Ibbotson S; Russell-Jones R; ;
Br J Dermatol; 2006 Jan; 154(1):7-20. PubMed ID: 16403088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
